Currently, human CD34+ cells are being explored as a potential regenerative therapy for ischemic conditions, such as ischemic cardiomyopathy or peripheral ischemia, because this cell population includes endothelial progenitor cells.13 The gene discussed is CD34; the disease is ischemic cardiomyopathy.